Beta adrenoagonists with a predominant effect on beta2-adrenergic
receptors (localized, particularly in the bronchi, myometrium, blood
This medication prevents and reduces or eliminates bronchospasm, reduces
the resistance in the airways, increases the vital capacity. It
prevents the release of histamine, slow reacting substance from mast
cells and factors chemotaxis of neutrophils. Compared with other drugs
of this group has a less pronounced positive chrono-and inotropic effect
on myocardium. It widen of coronary arteries, practically does not
reduce blood pressure. Has tocolytic effect, lowering the tone and the
contractile activity of the myometrium.
When using an aerosol there is a rapid absorption of albuterol
(salbutamol) in the blood, but its concentration in plasma when used in
recommended doses are very low or below detection limit.
After oral salbutamol is well absorbed from the gastrointestinal tract.
Plasma protein binding is 10%. Metabolised with "first pass" through the
liver and possibly in the wall of the intestine, the main metabolite -
inactive sulfate conjugate. salbutamol is not metabolised in the lungs,
thus its ultimate metabolism and excretion following inhalation depends
on the method of application, which defines the relationship between
inhaled salbutamol and unintentionally swallowed.
T1/2 from plasma is 2-7 hours. albuterol (salbutamol) is rapidly
excreted in the urine as metabolites and unchanged substance, in small
amounts excreted in the feces.
Why is Farcolin prescribed?
The prevention and relief of bronchospasm in all forms of bronchial
asthma. Reversible airway obstruction in chronic bronchitis and
emphysema, bronchial obstruction in children.
Threatening preterm labor with uterine contractions; birth to 37-38
weeks of pregnancy; isthmic-cervical insufficiency, decrease in fetal
heart rate, depending on uterine contractions during opening of the
cervix and expulsion. As a preventive measure during surgery on the
pregnant uterus (the imposition of a circular suture with the lack of
internal os of the uterus).
Dosage and administration
For oral use as a means of extending the broncho adults and children
over 12 years - 2.4 mg 3-4 times / day; if necessary, the dose may be
increased to 8 mg 4 times / day. Children aged 6-12 years - 2 mg 3-4
times / day; children 2-6 years - 1-2 mg 3 times / day.
For inhalation use dose depends on the applied dosage form, frequency of
use depends on the testimony and the clinical situation.
As a tocolytic agent used as IV infusion in dose of 1-2 mg.